Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation and aggregation into neurofibrillary tangles (right). [Courtesy of Eli ...

Leerink Partners analyst Lili (Aurélie) Nsongo has reiterated their bullish stance on VYGR stock, giving a Buy rating yesterday.

An international collaboration led by RIKEN researchers has discovered how unusual spherical structures form in the brains of ...

In Japan, clinical use is climbing faster, with about 4,500 people now on the drug. ARIA rates in Japan are half those in the U.S., which was also the case in the Phase 3 Clarity trial. Meanwhile, use ...

Actinogen Medical (ASX:ACW) reports that its well-anticipated Alzheimer’s disease clinical trial is on track, with an interim ...

We fully endorse the Editorial1 on the negative opinion of the European Medicines Agency of the use of lecanemab for the treatment of early Alzheimer's disease. Investigators from the European ...

From advanced imaging to AI-driven analysis, we seek studies that not only push the boundaries of what is possible but also directly address the clinical needs of conditions such as ALS, Autism, ...

Tested in animal models, it may extend cognitive function by 10-15 years, offering a potential breakthrough in Alzheimer’s ...

Researchers at Texas A&M University have developed a nasal spray shown to delay disease progression in animals -- fueling hope it could one day work in humans.

As we count down toward the December readout of Cassava Sciences’ simufilam Phase 3 clinical trial in Alzheimer’s disease, it ...

the Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital, and partner institutions have discovered ...